Novo Nordisk A/S and BIOCORP Production SA announced June 5th that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP1 at a price of 35.00 Euros per share in cash, representing a total equity [...]The post Novo Nordisk Is Negotiating to Buy French Device-Maker Biocorp for $165M appeared first on Healthcare Weekly.